A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy.
David MichelsonWilliam W ChinRobert H DworkinRoy FreemanDavid N HerrmannRalph MazitschekRodica Pop-BusuiAziz ShaibaniJames VornovMelissa JonesMatthew JarpeBrittany HaderTheresa VieraMichelle HylanTim KachmarSimon JonesPublished in: Pain reports (2023)
These results do not support the use of the HDAC6 inhibitor ricolinostat as a treatment for neuropathic pain in DPN for periods up to 12 weeks.